392 related articles for article (PubMed ID: 15971433)
1. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.
Ahmadi-Simab K; Lamprecht P; Gross WL
Clin Exp Rheumatol; 2005; 23(3):402-3. PubMed ID: 15971433
[TBL] [Abstract][Full Text] [Related]
2. Role of iloprost and bosentan in pulmonary arterial hypertension.
Saleh JA
Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
[TBL] [Abstract][Full Text] [Related]
3. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Hoeper MM; Leuchte H; Halank M; Wilkens H; Meyer FJ; Seyfarth HJ; Wensel R; Ripken F; Bremer H; Kluge S; Hoeffken G; Behr J
Eur Respir J; 2006 Oct; 28(4):691-4. PubMed ID: 17012628
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
[TBL] [Abstract][Full Text] [Related]
5. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
6. Sustained success of therapy with inhaled iloprost for severe pulmonary arterial hypertension associated with systemic sclerosis and pulmonary fibrosis.
Ahmadi-Simab K; Köhler A; Gross WL
Clin Exp Rheumatol; 2007; 25(5):760-2. PubMed ID: 18078629
[TBL] [Abstract][Full Text] [Related]
7. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of long-term oral monotherapy and additional effect of inhaled iloprost in patients with severe idiopathic pulmonary arterial hypertension].
Onen ZP; Sayın T; Akkoca Yıldız O; Ozdemir Kumbasar O; Karabıyıkoğlu G
Anadolu Kardiyol Derg; 2010 Oct; 10(5):458-60. PubMed ID: 20929705
[No Abstract] [Full Text] [Related]
9. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Fruhwald FM; Kjellström B; Perthold W; Wonisch M; Maier R; Klein W
J Heart Lung Transplant; 2005 May; 24(5):631-4. PubMed ID: 15896766
[TBL] [Abstract][Full Text] [Related]
10. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
12. Inhaled iloprost for the control of pulmonary hypertension.
Krug S; Sablotzki A; Hammerschmidt S; Wirtz H; Seyfarth HJ
Vasc Health Risk Manag; 2009; 5(1):465-74. PubMed ID: 19475782
[TBL] [Abstract][Full Text] [Related]
13. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
14. Inhaled iloprost for therapy in pulmonary arterial hypertension.
Ewert R; Gläser S; Bollmann T; Schäper C
Expert Rev Respir Med; 2011 Apr; 5(2):145-52. PubMed ID: 21510725
[TBL] [Abstract][Full Text] [Related]
15. [Combination therapy in patients with pulmonary arterial hypertension].
Ewert R; Opitz CF; Schäper C; Gläser S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
[TBL] [Abstract][Full Text] [Related]
16. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W
Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951
[TBL] [Abstract][Full Text] [Related]
17. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
19. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy.
Kramm T; Eberle B; Guth S; Mayer E
Eur J Cardiothorac Surg; 2005 Dec; 28(6):882-8. PubMed ID: 16242948
[TBL] [Abstract][Full Text] [Related]
20. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
